Browsing by Subject "Triacylglycerol"

Article

Are the effects of tamoxifen on the serum lipid profile modified by apolipoprotein E phenotypes?

Liberopoulos, E. N.; Karabina, S. A.; Tselepis, A.; Bairaktari, Eleni Th; Nikolaides, C.; Pavlidis, Nicholas; Elisaf, Moses S. (2002)

Background: Tamoxifen has favorable effects on the serum lipid profile. It has been suggested that the apolipoprotein (Apo) E phenotype can influence serum lipid parameters; the ApoE allele 4 (ApoE4) is associated with ...

Article

The association between plasminogen activator inhibitor type 1 (PAI-1) levels, PAI-1 4G/5G polymorphism, and myocardial infarction: A mendelian randomization meta-analysis

Nikolopoulos, Georgios K.; Bagos, Pantelis G.; Tsangaris, I.; Tsiara, Chrissa G.; Kopterides, Petros; Vaiopoulos, A.; Kapsimali, Violetta; Bonovas, Stefanos; Tsantes, Argirio E. (2014)

Background: The circulating levels of plasminogen activator inhibitor type 1 (PAI-1) are increased in individuals carrying the 4G allele at position -675 of the PAI-1 gene. In turn, overexpression of PAI-1 has been found ...

Article

The beneficial effect of tamoxifen on serum lipoprotein-a levels: An additional anti-atherogenic property

Elisaf, Moses S.; Bairaktari, Eleni Th; Nikolaides, C.; Fountzilas, George; Tzallas, C. S.; Siamopoulos, K. C.; Tsolas, O.; Pavlidis, Nicholas (1996)

It has recently been suggested that increased lipoprotein (a) levels are an independent risk factor for coronary heart disease. It has also been reported that tamoxifen can induce changes in blood lipid values. In this ...

Article

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

Elisaf, Moses S.; Bairaktari, Eleni Th; Nikolaides, C.; Kakaidi, B.; Tzallas, C. S.; Katsaraki, A.; Pavlidis, Nicholas (2001)

Hormonal therapy plays a central role in the overall treatment of breast cancer. Aromatase inhibitors can inhibit the aromatase enzyme system resulting in a reduction of oestrogens. Letrozole is a non-steroidal aromatase ...

Article

Efficacy and safety of more intensive lowering of LDL cholesterol [1]

Bonovas, Stefanos; Nikolopoulos, Georgios K.; Sitaras, N. M. (2011)

Article

Metabolic syndrome and its components as predictors of all-cause mortality and coronary heart disease in type 2 diabetic patients

Protopsaltis, I. D.; Nikolopoulos, Georgios K.; Dimou, Eftihia; Brestas, Paris; Kokkoris, Stelios; Korantzopoulos, Panagiotis; Melidonis, Andreas (2007)

Background: There is no consistent evidence regarding the prognostic value of metabolic syndrome (MS) in predicting all-cause mortality and coronary heart disease (CHD) risk among type 2 diabetic patients. We sought to ...

Article

Re: The influence of tamoxifen on serum triglycerides

Elisaf, Moses S.; Bairaktari, Eleni Th; Pavlidis, Nicholas (2000)

Article

Tamoxifen-induced severe hypertriglyceridemia and pancreatitis

Elisaf, Moses S.; Nakou, K.; Liamis, G.; Pavlidis, Nicholas (2000)

Tamoxifen exhibits favorable effects on the lipid and lipoprotein profile since it decreases the total and LDL cholesterol levels as well as the Lp(a) levels. Additionally, a small increase in serum triglycerides is commonly ...